Sanofi SA

NASDAQ:SNYUnited States

Today

Show headlines and story abstract

• Regeneron, Sanofi's Dupixent Drug Meets Main Goal in 2 Late-Stage Trials, from 1 hour ago by MT Newswires

  1 hour ago by MT Newswires
  Companies Mentioned: REGN, SNY
  04:08 AM EDT, 09/11/2024 (MT Newswires) -- Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Wednesday that a confirmatory phase 3 study of Dupixent met primary and key secondary goals in treating patients with uncontrolled, biologic-naive chro...

• DJ Sanofi's Dupixent Drug Achieves Improvement for Skin Diseases, from 3 hours ago by Dow Jones

  3 hours ago by Dow Jones
  Companies Mentioned: REGN, SNY
  
  By Andrea Figueras
  
  Sanofi said its dupixent drug achieved significant improvements for the treatment of two skin diseases.
  
  The French pharmaceutical company said Wednesday that the drug met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe bullous pemphigoid, or BP.
  

• Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU, from 4 hours ago by Dow Jones

  4 hours ago by Dow Jones
  Companies Mentioned: SNY
  
  Arnaud Delépine | + 33 6 73 69 36 93 |arnaud.delepine@sanofi.com
  
  Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
  
  Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
  

• Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study, from 4 hours ago by Dow Jones

  4 hours ago by Dow Jones
  Companies Mentioned: SNY
  
  for the treatment of bullous pemphigoid and/or chronic pruritus of unknown origin as discussed in this press release as well as other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including the studies discussed or referenced in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA(R) (aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2023 and its Form 10-Q for the quarterly period ended June 30, 2024. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
  

• Dupixent(R) (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial, from 4 hours ago by Dow Jones

  4 hours ago by Dow Jones
  Companies Mentioned: REGN, SNY
  
  Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).